Does CareFirst BlueCross BlueShield Cover Eliquis?

What Is Eliquis and Why Do Patients Need It?

Eliquis is the brand name for apixaban, a direct oral anticoagulant (DOAC) that inhibits Factor Xa in the coagulation cascade. The FDA approved apixaban in 2012 for stroke and systemic embolism prevention in adults with nonvalvular atrial fibrillation [1]. Subsequent approvals extended its use to deep vein thrombosis (DVT) treatment, pulmonary embolism (PE) treatment, and post-surgical prophylaxis following hip or knee replacement surgery [1].

Clinical Evidence Supporting Apixaban

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily with warfarin in patients with atrial fibrillation and found a 21% relative risk reduction in stroke or systemic embolism (1.27% vs. 1.60% per year, P<0.001) and a 31% reduction in major bleeding [2]. The AMPLIFY trial (N=5,395) demonstrated that apixaban was non-inferior to conventional warfarin-based therapy for recurrent VTE and superior for major bleeding (0.6% vs. 1.8%, P<0.001) [3].

These outcomes matter for formulary coverage decisions because payers use clinical evidence when designing prior authorization criteria. Plans that require step therapy toward warfarin should note the superior bleeding profile documented in ARISTOTLE and AMPLIFY.

FDA-Approved Dosing Regimens

Approved doses range from apixaban 2.5 mg twice daily (post-surgical prophylaxis, dose-reduced AF patients meeting two of three criteria) to 10 mg twice daily for the first seven days of acute DVT or PE treatment, followed by 5 mg twice daily [1]. Prescribers must document the indication and dose selection in prior authorization requests because CareFirst's criteria are indication-specific.

How CareFirst BlueCross BlueShield Formularies Work

CareFirst administers multiple distinct plan types across Maryland, Washington D.C., and Northern Virginia, and each carries its own drug formulary. Understanding how these formularies are structured explains why two CareFirst members can have very different cost-sharing for the same drug.

Formulary Tiers Explained

Most CareFirst commercial formularies use a four- or five-tier structure:

• Tier 1: Preferred generics. Lowest copay, typically $0, $15.
• Tier 2: Non-preferred generics and preferred brand drugs. $20, $45 copay range on many plans.
• Tier 3: Non-preferred brand drugs. $50, $100 copay or 20 to 40% coinsurance on many plans.
• Tier 4: Specialty drugs. Coinsurance-based, often 25 to 33% of the drug cost.

Eliquis lands on Tier 3 in most CareFirst commercial formularies and on Tier 4 in some high-deductible and specialty-tier designs. CareFirst's Medicare Advantage plans (BlueChoice 65 Plus, for example) follow CMS formulary rules and list Eliquis on Tier 4 or Tier 5.

Generic Apixaban and Its Impact on Coverage

Bristol-Myers Squibb's exclusivity on apixaban ended in 2023, and the FDA approved generic apixaban from multiple manufacturers [4]. CareFirst began placing generic apixaban on Tier 1 or Tier 2 of updated formularies. If your plan includes generic apixaban, step therapy may now require a generic trial before brand Eliquis is covered at the lower cost-sharing tier. Clinically, generic apixaban uses the same active molecule and bioequivalence standards the FDA requires for all generic drugs [4].

Does CareFirst Require Prior Authorization for Eliquis?

Prior authorization (PA) is required for Eliquis on the majority of CareFirst's commercial and Medicare Advantage plans. Without an approved PA, the pharmacy cannot adjudicate the claim and you pay the full cash price, which averages $593, $620 for a 30-day supply of 60 tablets.

Common CareFirst PA Criteria for Apixaban

CareFirst's PA criteria for apixaban typically require the prescriber to document:

1. The specific FDA-approved indication (AF, DVT, PE, or post-surgical prophylaxis).
2. A CHA2DS2-VASc score of 2 or higher for atrial fibrillation patients (consistent with American Heart Association/American College of Cardiology guidelines, which recommend anticoagulation for a score of 2 in men or 3 in women) [5].
3. Documentation of a clinical reason why warfarin is not appropriate OR evidence that step therapy with warfarin was tried and failed, caused adverse effects, or is contraindicated.
4. Creatinine clearance and weight (to verify dose selection aligns with FDA labeling).

The ACC/AHA 2023 Atrial Fibrillation Guideline states: "In patients with AF and a CHA2DS2-VASc score of 2 or greater in men or 3 or greater in women, oral anticoagulant therapy is recommended to reduce the risk of stroke and systemic thromboembolism. DOACs are recommended over vitamin K antagonists in eligible patients." [5] That explicit guideline preference for DOACs over warfarin is your strongest clinical argument when challenging a step-therapy denial.

Step Therapy Requirements

Step therapy (also called "fail-first" requirements) obliges patients to try and fail warfarin before the plan approves a DOAC like apixaban. Many states have passed step-therapy reform laws: Maryland (where most CareFirst members are located) enacted step-therapy legislation that requires insurers to grant exemptions when step therapy is clinically inappropriate [6]. Grounds for an exemption in Maryland include:

• The required first-step drug is contraindicated (e.g., mechanical heart valve, antiphospholipid syndrome for some DOACs).
• The required drug is expected to cause adverse reactions based on patient history.
• The required drug was tried in the past and failed.
• The prescribing clinician determines the step-therapy drug is not in the patient's best clinical interest.

A simple framework for securing step-therapy exemptions: First, gather the patient's complete anticoagulation history, prior INR records, and any documented adverse events with warfarin. Second, identify the Maryland-specific exemption category that fits. Third, have the prescriber write a detailed clinical letter citing the ACC/AHA DOAC preference recommendation [5] and the ARISTOTLE bleeding data [2]. Fourth, submit the exemption request simultaneously with the PA request to avoid a second cycle of delays.

How Much Does Eliquis Cost With CareFirst?

Out-of-pocket cost depends on your plan's tier assignment, your deductible status, and whether you have hit your out-of-pocket maximum. The numbers below reflect typical CareFirst commercial plan ranges and should be verified on your specific plan's Summary of Benefits or through the CareFirst member portal.

Before Your Deductible Is Met

On high-deductible health plans (HDHPs), you pay the full negotiated rate until your deductible is satisfied. CareFirst's negotiated rate for brand Eliquis is typically lower than the retail cash price but may still run $300, $500 per 30-day supply before deductible.

After Your Deductible Is Met

Once your deductible clears, Tier 3 cost-sharing on CareFirst commercial plans often means a $60, $100 copay or 25 to 35% coinsurance per 30-day fill. On a Tier 4 specialty classification, 25 to 33% coinsurance on a $500 negotiated price equals $125, $165 per month.

Patient Assistance and Manufacturer Copay Cards

Bristol-Myers Squibb and Pfizer (co-developers of Eliquis) offer the Eliquis 360 Support program, which provides eligible commercially insured patients a copay card that can reduce out-of-pocket costs to as low as $10 per month. The copay card is not usable with federal programs (Medicare, Medicaid, TRICARE) per federal anti-kickback statute requirements. Patients on Medicare Advantage CareFirst plans must look instead at the Extra Help / Low Income Subsidy (LIS) program administered by CMS [7].

What to Do If CareFirst Denies Coverage for Eliquis

A coverage denial is not a final answer. Federal law (ACA Section 2719 and ERISA for self-insured plans) and Maryland state law guarantee multiple levels of appeal [8].

Internal Appeal

You have 180 days from the denial notice to file an internal appeal with CareFirst. The insurer must respond within 30 days for non-urgent care or 72 hours for urgent/concurrent care [8]. Include in your appeal package:

• The prescriber's letter citing the ACC/AHA guideline preference for DOACs [5].
• Relevant clinical notes documenting the indication, CHA2DS2-VASc score, and any prior anticoagulant history.
• Published evidence: the ARISTOTLE trial showing a 31% major bleeding reduction with apixaban vs. Warfarin [2] and the AMPLIFY trial showing superior safety in VTE [3].
• If step therapy is the denial reason, cite Maryland's step-therapy exemption statute and explain which exemption category applies [6].

External Review

If the internal appeal fails, you can request an independent external review. Maryland participates in the federal external review process. The external reviewer is independent of CareFirst and their decision is binding on the insurer. Industry-wide, approximately 39 to 59% of external reviews result in overturning the insurer's decision [9].

Expedited Appeal for Urgent Cases

Acute DVT, PE, or a patient with high-risk AF awaiting cardioversion qualifies for an expedited appeal. The insurer must respond within 72 hours. Documenting clinical urgency in writing at the time of the PA request can automatically trigger expedited review.

Eliquis Versus Other Anticoagulants on the CareFirst Formulary

Knowing how CareFirst tiers competing drugs helps you and your prescriber identify covered alternatives if needed.

Warfarin (Coumadin)

Warfarin is a Tier 1 generic on virtually every CareFirst formulary. Cost is minimal, often $4, $10 per month. The trade-off is mandatory INR monitoring every 2 to 4 weeks, a narrow therapeutic window, and numerous food and drug interactions. The ACC/AHA 2023 guideline recommends DOACs preferentially over warfarin when eligible [5].

Rivaroxaban (Xarelto)

Rivaroxaban is another Factor Xa inhibitor and competes directly with apixaban. CareFirst sometimes places rivaroxaban on a different preferred tier than apixaban depending on negotiated rebate agreements, so it may be available at lower cost-sharing. In the ROCKET-AF trial (N=14,264), rivaroxaban was non-inferior to warfarin for stroke prevention in AF patients (1.7% vs. 2.2% per year for the primary endpoint, P<0.001 for non-inferiority) [10]. Compared head-to-head with apixaban in observational data, apixaban showed a modestly lower bleeding risk in some analyses, though no prospective RCT has directly compared the two agents.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor FDA-approved for AF and VTE. The RE-LY trial (N=18,113) found dabigatran 150 mg twice daily superior to warfarin for stroke prevention (1.11% vs. 1.69% per year, P<0.001) [11]. CareFirst may tier dabigatran differently than apixaban; check your specific formulary.

Generic Apixaban

As noted above, generic apixaban launched in 2023 and carries FDA-mandated bioequivalence. If your CareFirst plan has updated its formulary to include generic apixaban, this is likely the lowest-cost route to the same active molecule as brand Eliquis [4].

How to Check Your Specific CareFirst Plan's Eliquis Coverage Right Now

Coverage details change annually during Open Enrollment and mid-year when formularies update. The most reliable verification steps are:

Step 1: Use the CareFirst Online Formulary Tool

Log in to your CareFirst member account at carefirst.com. Manage to "Pharmacy" and then "Drug Formulary." Search for "apixaban" (the generic name) or "Eliquis." The tool shows the current tier, any PA or step-therapy requirements, and quantity limits for your specific plan.

Step 2: Call the CareFirst Pharmacy Benefits Line

The member services number appears on your insurance card. Ask the representative specifically: (a) Is Eliquis covered on my formulary? (b) What tier? (c) Is prior authorization required? (d) Is step therapy required? (e) What is my copay or coinsurance after my deductible? Document the representative's name and the date and time of the call.

Step 3: Have Your Prescriber Submit a PA Early

Even if the drug is on-formulary, PA requirements mean coverage does not activate until approval. Submitting the PA before the prescription is written saves days. Most PA decisions come back within 1 to 3 business days for non-urgent requests.

Step 4: Ask the Pharmacy to Run a Test Claim

A retail pharmacist can run a test adjudication before you pick up the prescription. This reveals the exact copay CareFirst will charge at point of sale and whether a PA hold is in place.

Special Populations: Medicare Advantage CareFirst Plans

CareFirst's Medicare Advantage products (including BlueChoice 65 Plus plans) follow CMS formulary requirements and the annual Medicare Part D coverage phases. In 2024, the catastrophic coverage threshold dropped to $8,000 in true out-of-pocket costs, offering meaningful protection for high-cost drugs like brand Eliquis [7].

Under the Inflation Reduction Act of 2022, starting in 2025 Medicare Part D enrollees pay a maximum of $2,000 in annual out-of-pocket drug costs, eliminating the coverage gap (donut hole) that previously caused high costs mid-year [7]. CareFirst Medicare Advantage members on Eliquis should see significantly lower annual exposure once this cap takes effect.

Low-income subsidy (LIS) / Extra Help recipients on CareFirst Medicare Advantage plans face very low or $0 cost-sharing for covered drugs including apixaban, subject to formulary placement [7].

Talking to Your Doctor About Coverage and Clinical Alternatives

When cost or coverage barriers arise, a productive conversation with your prescriber should include:

• Presenting your plan's Explanation of Benefits or formulary printout showing the tier and PA requirements.
• Asking whether generic apixaban (now FDA-approved) would satisfy your clinical needs at lower cost [4].
• Discussing whether rivaroxaban or dabigatran are on a preferred tier on your plan.
• For AF patients with a CHA2DS2-VASc score of 2 or higher, any DOAC is guideline-consistent [5]. The choice among them may reasonably be driven by formulary economics.
• Asking the prescriber's office to check whether they have enrollment materials for the Eliquis 360 Support copay assistance program.

Never stop anticoagulation without physician guidance. Abrupt discontinuation in patients with AF or active VTE carries real thrombotic risk.